Business Wire

MA-EVERBRIDGE

12.10.2020 13:32:14 CEST | Business Wire | Press release

Share
Everbridge Appoints World-renowned Technologist, and “One of the Most Influential People of the 21st Century,” as Chief Customer Experience Officer to Innovate the Next Generation of Critical Event Management (CEM)

Everbridge , Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM ), today announced the appointment of Dr. John Maeda to the new role of Chief Customer Experience Officer. As a renowned technologist and designer, Dr. Maeda will help innovate the next generation of critical event management for every stakeholder in a world where safety and resiliency standards are forever changed by the coronavirus pandemic. Recognized as one of the “75 Most Influential People of the 21st Century” by Esquire , Dr. Maeda brings unmatched credentials to Everbridge as an MIT-trained engineer and researcher, public company board member and C-Level executive, Silicon Valley venture capital partner, digital transformation thought leader and acclaimed TED-talk presenter who combines world-class technology and design expertise with a passion for diversity, equity, and inclusion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201012005215/en/

Serving a powerful mission to keep people safe and organizations running, Everbridge was founded in the aftermath of 9/11, helping organizations manage major threats for close to 20 years since. As the pioneer of critical event management, Everbridge, and its mission, now grow in importance every day as the world navigates a generational ‘black swan’ event resulting from coronavirus. Impacting nearly every individual on the planet, COVID-19 dramatically changes how government leaders, CEOs and boards of companies, citizens, employees, public health workers, and front line emergency responders, must prepare for a variety of critical events that can impact people, operations, supply chain and brand.

“As COVID-19 remains a pervasive and persistent threat further compounded by other critical events such as hurricanes, wildfires, and cyberattacks, the importance of critical event management to all individuals and organizations continues to increase,” said David Meredith, CEO of Everbridge. “As the pioneer and leader in Critical Event Management, Everbridge continues to elevate the experience for stakeholders at each touch point with our technology.”

Continued Meredith, “Our mission, market-leading technology, and leadership position in an increasingly relevant and critical sector, enables us to attract the very best talent to Everbridge which Dr. John Maeda represents. John’s innovative approach to digital transformation and design will be instrumental as Everbridge optimizes the experience for individuals, organizations and governments to meet the challenges and risks of an uncertain world.”

“The stakes of managing critical events well, and more proactively, have never been higher, as typified by the coronavirus,” said Dr. John Maeda. “I’m very excited to apply my experience digitally transforming how organizations communicate and solve business problems to this incredibly important area. Everbridge, as the category creator and clear leader in critical event management, offers the platform where I can have the most impact in helping to save lives and livelihoods, a truly fulfilling mission.”

Prior to Everbridge, Dr. Maeda served as Chief Experience Officer at $11+B revenue communications and technology firm Publicis where he led their CX/DX practices to be recognized by Forrester and Gartner as Leaders. Maeda serves on the Boards of Sonos Inc. and the Cooper Hewitt Smithsonian Design Museum. He held leadership positions with Automattic, the parent company of WordPress.com and formerly the world’s largest all-distributed tech company; advertising agency Wieden + Kennedy; and the venture capital firm Kleiner Perkins; worked as an advisor to Google and eBay; served as president of the Rhode Island School of Design; and began his early career at MIT at the intersection of computer science and visual design.

Maeda authored several celebrated books including How To Speak Machine , The Laws of Simplicity , and Redesigning Leadership . He appeared as a speaker all over the world, from Davos to Beijing to São Paulo to New York, his talks for TED received millions of views, and Maeda’s Twitter feed was named one of the 140 best by TIME Magazine .

Maeda received the White House’s National Design Award, the Tribeca Film Festival’s Clayton Christensen Disruptive Innovation Award for STEM to STEAM, the Blouin Foundation’s Creative Leadership Award, the AIGA Medal, the Raymond Loewy Foundation Prize, the Mainichi Design Prize, the Tokyo Type Director’s Club Prize, and induction into the Art Director’s Club Hall of Fame.

Maeda holds BS and MS degrees in Electrical Engineering and Computer Science from Massachusetts Institute of Technology (MIT), an MBA from Arizona State University, a PhD from University of Tsukuba in Japan, and honorary doctorate degrees from Drexel University, Simon Fraser University, and Maryland Institute College of Art.

Dr. Maeda will join keynote speakers this week including a former World Head of State , as well as the Director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH) Dr. Anthony Fauci, Virgin Group Founder Sir Richard Branson, and renowned neurosurgeon and CNN Chief Medical Correspondent Dr. Sanjay Gupta, at Everbridge’s “COVID-19 R2R: The Road to Recovery” virtual leadership summit. To learn more, please visit Everbridge’s event registration page .

About Everbridge

Everbridge , Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order to Keep People Safe and Businesses Running™. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 5,300 global customers rely on the company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication devices, and track progress on executing response plans. The company’s platform sent over 3.5 billion messages in 2019 and offers the ability to reach over 600 million people in more than 200 countries and territories, including the entire mobile populations on a country-wide scale in Australia, Greece, Iceland, the Netherlands, New Zealand, Peru, Singapore, Sweden, and a number of the largest states in India. The company’s critical communications and enterprise safety applications include Mass Notification, Incident Management, Safety Connection™, IT Alerting, Visual Command Center®, Public Warning, Crisis Management, Community Engagement™ and Secure Messaging. Everbridge serves 8 of the 10 largest U.S. cities, 9 of the 10 largest U.S.-based investment banks, 47 of the 50 busiest North American airports, 9 of the 10 largest global consulting firms, 8 of the 10 largest global auto makers, all 4 of the largest global accounting firms, 9 of the 10 largest U.S.-based health care providers, and 7 of the 10 largest technology companies in the world. Everbridge is based in Boston and Los Angeles with additional offices in Lansing, San Francisco, Abu Dhabi, Beijing, Bangalore, Kolkata, London, Munich, New York, Oslo, Singapore, Stockholm and Tilburg. For more information, visit www.everbridge.com , read the company blog , and follow on LinkedIn , Twitter , and Facebook .

Cautionary Language Concerning Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our critical communications and enterprise safety applications and our overall business, our market opportunity, our expectations regarding sales of our products, our goal to maintain market leadership and extend the markets in which we compete for customers, and anticipated impact on financial results. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the ability of our products and services to perform as intended and meet our customers’ expectations; our ability to successfully integrate businesses and assets that we may acquire; our ability to attract new customers and retain and increase sales to existing customers; our ability to increase sales of our Mass Notification application and/or ability to increase sales of our other applications; developments in the market for targeted and contextually relevant critical communications or the associated regulatory environment; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we have not been profitable on a consistent basis historically and may not achieve or maintain profitability in the future; the lengthy and unpredictable sales cycles for new customers; nature of our business exposes us to inherent liability risks; our ability to attract, integrate and retain qualified personnel; our ability to maintain successful relationships with our channel partners and technology partners; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of personally identifiable information; our ability to protect our intellectual property rights, and the other risks detailed in our risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 28, 2020. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye